Splice-Switching Antisense Oligonucleotide Controlling Tumor Suppressor REST Is a Novel Therapeutic Medicine for Neuroendocrine Cancer

0
176
Researchers investigated amido-bridged nucleic acid-based splice-switching oligonucleotides targeting RE1-silencing transcription factor (REST) splicing as a novel therapy.
[Molecular Therapy – Nucleic Acids]
Full ArticleGraphical Abstract